ProCE Banner Activity

ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy

Slideset Download
Conference Coverage

Addition of asciminib to imatinib led to higher rate of DMR vs continued imatinib or switch to nilotinib in patients with chronic-phase chronic myeloid leukemia not achieving DMR with &ge 1 year of imatinib therapy.

Released: December 13, 2022

Expiration: December 12, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen